TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04154137

Intervention type: OTHER
Intervention: Questionnaire
Description: Enrolled patients will fill out a modified version of a previously validated written questionnaire, including two different sections. The first comprises basic demographic information, including age, sex and ethnicity, and a screening section for symptoms consistent with irritable bowel syndrome (IBS) in accordance with the Rome III criteria, also including their past gastrointestinal, allergic and psychiatric history. The second section enquires for self-reported gluten-related symptoms. Participants will be also asked for their use of a gluten-free diet and if they had seen a healthcare professional for their symptoms. A reported diagnosis of celiac disease and wheat allergy in the population group is defined by those who had a doctor diagnosis of celiac disease and wheat allergy and are also taking a gluten-free diet.
Study: NCT01187576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-professional team intervention with PAR, lifestyle brochure
Description: Multi-professional team intervention with PAR, lifestyle brochure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ordinary recommendations on health behaviours, lifestyle brochure
Description: Ordinary recommendations on health behaviours, lifestyle brochure
Study: NCT03684096

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: non-estrogenic pollen extract PCC-100
Description: non-estrogenic pollen extract PCC-100

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo -non-estrogenic pollen extract PCC-100
Study: NCT01558921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: M1 scheme
Description: short course 5 x 5 Gy radiation scheme is followed by six cycles of combination chemotherapy (capecitabine and oxaliplatin (CAPOX)) and surgery. FOLFOX4 may be given as alternative for CAPOX

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard long course chemoradiotherapy
Description: long course chemoradiotherapy followed by surgery. Optional adjuvant chemotherapy (CAPOX or FOLFOX) is allowed in the control group.
Study: NCT03601351

Intervention type: OTHER
Intervention: ELISA for MOR-1 expression
Description: To evaluate MOR-1 expression differences by immunohistochemical analysis (ELISA - semiquantitative) in paraffin samples from patients with colorectal cancer stage II / III submitted scheduled colorectal surgery between the tumor tissue and the adjacent nontumorous tissue.

Intervention type: OTHER
Intervention: ELISA for MOR-1 expression
Description: To evaluate MOR-1 expression differences by immunohistochemical analysis (ELISA - semiquantitative) in paraffin samples from patients with colorectal cancer stage II / III submitted scheduled colorectal surgery between the tumor tissue and the adjacent nontumorous tissue.
Study: NCT01821586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified ORS-1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified ORS-2 (ReSoMal)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified ORS-3 (Benefibre)
Study: NCT02945267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab plus S1
Description: Nimotuzumab Injection: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area\<1.5 m2) or 60 mg (Body surface area\>1.5 m2) ,oral,d1-d14, every three weeks for a cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus S1
Description: Placebo: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area\<1.5 m2) or 60 mg (Body surface area\>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
Study: NCT00344019

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo pre-PCI for ACS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80mg
Description: atorvastatin 80 mg pre-angio/PCI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening
Description: Patients signed consent to be screened for eligibility for randomization to placebo vs. study drug (atorvastatin)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Screening
Description: Patients signed consent to be screened for eligibility for randomization to placebo vs. study drug (atorvastatin)
Study: NCT00843193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INTRAVENOUS GSK679586
Description: GSK679586 will be provided as a clear or colorless to pale yellow liquid with the unit dose strength of 10mg/kg and will be infused over an hour. The infusion will be delivered by a programmable infusion pump

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: INTRAVENOUS PLACEBO
Description: Clear or colorless 0.9% sodium chloride saline solution will be infused over an hour. The infusion will be delivered by a programmable infusion pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLUTICASONE PROPIONATE
Description: Subjects will be supplied fluticasone propionate at Screening, Run-in and when needed during the study. Subjects will be up-titrated to 1000 μg/day and those who were already taking greater than equal to 1000 μg/day fluticasone propionate or equivalent prior to the study will remain on their pre-study dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FLUTICASONE PROPIONATE
Description: Subjects will be supplied fluticasone propionate at Screening, Run-in and when needed during the study. Subjects will be up-titrated to 1000 μg/day and those who were already taking greater than equal to 1000 μg/day fluticasone propionate or equivalent prior to the study will remain on their pre-study dose.
Study: NCT01648140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805 40 mg
Description: 20 mg tablet, round, 10-mm diameter, white to off-white, no markings

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805 60 mg
Description: 30 mg tablet, round, 10-mm diameter, white to off-white, no markings

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805 60 mg
Description: 30 mg tablet, round, 10-mm diameter, white to off-white, no markings

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2a
Description: 180 microgram per 0.5 mL prefilled syringe for single use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alpha-2a
Description: 180 microgram per 0.5 mL prefilled syringe for single use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2a
Description: 180 microgram per 0.5 mL prefilled syringe for single use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2a
Description: 180 microgram per 0.5 mL prefilled syringe for single use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200-mg tablet, capsule-shaped, light blue, film-coated, and debossed with 200 on 1 side and the logo 3RP on the other side
Study: NCT02803931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiogoniometry
Description: Cardiogoniometry cardiologic explorer, Enverdis GmbH medical solutions, Germany

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 12-lead ECG
Study: NCT01329224

Intervention type: OTHER
Intervention: Measurement of platelet anti-aggregation
Description: Whole blood impedance platelet aggregometry was performed with the Multiplate analyzer (Dynabyte, Munich, Germany) to test the response to ASA with arachidonic acid as the trigger.
Study: NCT02730507

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional straight rod
Description: Bras B: The control group is composed of patients operated with standard straight rods, which are bent in the operating room by the surgeon. In order to minimize potential bias derived from using different spinal systems or reduction techniques, the posterior instrumentation used in the control group must be the same (except the use of PSRs) than the experimental group.
Study: NCT02361762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized executive control training
Description: Children will play computerized training games designed to improve executive control skills. Each training activity is structured to achieve a particular type of training related to executive control and/or attention shifting.~Sessions last for 1 hour each and the intensity of intervention ranges from 5-10 hours. Children will receive training until all levels of all tasks have been passed or 10 hours, whichever happens first. All training exercises have a number of levels, and children progress to the next level by meeting specific criteria for accuracy and/or speed.~A trainer will be present during all sessions to help children comply with the training demands and to teach skills involved in completing challenging tasks.
Study: NCT03665376

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink load
Description: Administration of 5% Dextrose orally as a carbohydrate drink load two hours before surgery and as an oral sips eight hours after the surgery.
Study: NCT01648140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 200-mg tablet, capsule-shaped, light blue, film-coated, and debossed with 200 on 1 side and the logo 3RP on the other side

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200-mg tablet, capsule-shaped, light blue, film-coated, and debossed with 200 on 1 side and the logo 3RP on the other side

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200-mg tablet, capsule-shaped, light blue, film-coated, and debossed with 200 on 1 side and the logo 3RP on the other side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir
Description: 375 mg film-coated tablet
Study: NCT03665376

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Description: The ERAS intervention consisted of exposing patients to ERAS protocol of care as described by the ERAS Society® for the entire perioperative period. However, some of these ERAS protocols were modified to our local resources and requirements.
Study: NCT04346069

Intervention type: OTHER
Group type: OTHER
Intervention: PCIT (parent child interaction therapy)
Description: Parent child interaction therapy is a treatment strategy that nurture parent child relationship and teach effective parenting strategies to decrease child non compliance behavior (BodifordMcNeil; Hembree-Kigin, 2010).Parent-Child Interaction Therapy (PCIT; Eyberg; Robinson, 1982 ; Zisser; Eyberg, 2008 ) is a manualized parent training intervention that has received substantial empirical support in the treatment of disruptive behavior across multiple reviews (e.g., Brestan; Eyberg, 1998 ; Gallagher, 2003 ; Thomas \&amp; Zimmer-Gembeck, 2007 ). PCIT established strong relation among parenting, social learning, and attachment theories and proceeds.
Study: NCT02296099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine
Description: Liposomal bupivacaine 20 mL diluted with 10 mL normal saline. Ten mL of solution to be injected into the vaginal epithelium in the mid-urethral area and 10 mL injected into each of the trocar paths through the suprapubic incisions bilaterally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 30 mL total injected. Ten mL injected into the vaginal epithelium in the mid-urethral area and 10 mL will be injected into each of the trocar paths through the suprapubic incisions bilaterally.
Study: NCT04382859

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transversus abdominis plane (TAP) block with liposomal bupivacaine
Description: Transversus abdominis plane (TAP) blocks are safe and effective procedures for the provision of postoperative pain management following abdominal procedures (3) and have been widely used across specialties with reduction in postoperative pain and narcotic use (4-7).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane (TAP) block with liposomal bupivacaine
Description: Transversus abdominis plane (TAP) blocks are safe and effective procedures for the provision of postoperative pain management following abdominal procedures (3) and have been widely used across specialties with reduction in postoperative pain and narcotic use (4-7).
Study: NCT02077075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based weight loss program
Description: A 4-week web-based wellness program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based weight loss program
Description: A 4-week web-based wellness program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-line health coaching
Description: A 4-week web-based wellness program with weekly personalized on-line health coaching.
Study: NCT02306707

Intervention type: PROCEDURE
Intervention: Endoscopic Mucosal Resection
Study: NCT04196361

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Point of care ultrasound as part of routine physical examination
Study: NCT02822339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z12-030)
Study: NCT03362671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant Supported Mandibular Advancement Oral Appliance
Description: This device is a novel oral appliance that attached to orthodontic mini implants in the jaw and is designed to keep the jaw in an advanced position, opening the upper airway during sleep.
Study: NCT04564391

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: protein supplement
Description: protein supplement, daily 60 g of protein, 3 weeks of intervention; blinded to patients
Study: NCT03362671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic Mini Implant
Description: Small titanium devices that are fixed to the bone for the purpose of enhancing anchorage of other orthodontic devices.
Study: NCT01055951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solo MicroPump
Description: 30 days treatment days with an optional extension period of up to 6 month of treatment.
Study: NCT04667156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 new formulation 1(T1) , SHR6390 new formulation 2 (T2) and SHR6390 traditional formulatin were given in a single dose over three cycles
Study: NCT01201096

Intervention type: RADIATION
Intervention: 177Lutetium
Description: two cycles of 177Lutetium radioreceptor therapy within two month

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: about 9 month after finishing the receptor therapy liver transplantation takes place
Study: NCT00660036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Description: On Day 6 of an inpatient hospital stay: Based on the study design patients will be treated with one of three doses (3 mg/m\^2, 6 mg/m\^2 or 9 mg/m\^2), administered intravenously in 100 ml of 0.9% sodium chloride over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: On Days 1-3 of an inpatient hospital stay: 10 mg/m\^2 administered via IVPB (intravenous piggy-back) in 50ml normal saline (NS) over 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: On Days 1-5 of an inpatient hospital stay: 100 mg/m\^2 administered intravenously in 500 ml of 0.9% sodium chloride over 2 hours
Study: NCT04864652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHILLS Procedure
Description: CHILLS Cryotherapy procedure
Study: NCT04564391

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: protein supplement
Description: protein supplement, daily 60 g of protein, 3 weeks of intervention; blinded to patients

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo supplement
Description: Placebo supplement, daily intake of placebo, 3 weeks of intervention; blinded to patients
Study: NCT00151060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT01002859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sandimmum
Description: Intravenous injection of cyclosporine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Injection of NaCl solution
Study: NCT04667156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 new formulation 1(T1) , SHR6390 new formulation 2 (T2) and SHR6390 traditional formulatin were given in a single dose over three cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 new formulation 1(T1) , SHR6390 new formulation 2 (T2) and SHR6390 traditional formulatin were given in a single dose over three cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 new formulation 1(T1) , SHR6390 new formulation 2 (T2) and SHR6390 traditional formulatin were given in a single dose over three cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 new formulation 1(T1) , SHR6390 new formulation 2 (T2) and SHR6390 traditional formulatin were given in a single dose over three cycles
Study: NCT04748224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: a local anesthetic drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine plus dexmedetomidine
Description: bupivacaine is a local anesthetic drug plus dexmedetomidine is a new generation highly selective α2-adrenergic receptor (α2-AR) agonist that is associated with sedative and analgesic sparing effects
Study: NCT03213626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 MG
Description: To be taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib 100Mg Tab
Description: To be taken orally once daily
Study: NCT03828084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Combination drugs containing decitabine and tetrahydrouridine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Combination drugs containing decitabine and tetrahydrouridine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Combination drugs containing decitabine and tetrahydrouridine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: Combination drugs containing decitabine and tetrahydrouridine
Study: NCT03333057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV03
Description: Perfluorohexyloctane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV03
Description: Perfluorohexyloctane

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution (0.9% sodium chloride solution)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution (0.9% sodium chloride solution)
Study: NCT03969043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: The MRI examination will consist of a series of acquisition scans:~* Scanning Scan: for positioning the functional volume of interest.~* Task Scans: for exploring cerebral activation in emotional and action appraisal tasks during viewing high and low arousal stimuli and a localizer task .~* Anatomical MRI: for analyzing the functional images, and measuring volumes of gray and white substances.~* Resting state functional scan: for exploring cerebral activation during a rest activity.~* Diffusion Tension Imaging: for measuring structural connectivity.~* Perfusion imaging: scan for ensuring good perfusion conditions~All functional acquisitions will be performed in multi-slices in echoplanar mode using gradient echo sequences allowing the exploitation of the BOLD contrast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: The MRI examination will consist of a series of acquisition scans:~* Scanning Scan: for positioning the functional volume of interest.~* Task Scans: for exploring cerebral activation in emotional and action appraisal tasks during viewing high and low arousal stimuli and a localizer task .~* Anatomical MRI: for analyzing the functional images, and measuring volumes of gray and white substances.~* Resting state functional scan: for exploring cerebral activation during a rest activity.~* Diffusion Tension Imaging: for measuring structural connectivity.~* Perfusion imaging: scan for ensuring good perfusion conditions~All functional acquisitions will be performed in multi-slices in echoplanar mode using gradient echo sequences allowing the exploitation of the BOLD contrast.
Study: NCT03703375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romidepsin
Description: Romidepsin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine
Study: NCT02368340

Intervention type: OTHER
Intervention: Pulmonary function test
Description: Pulmonary function testing performed

Intervention type: OTHER
Intervention: Pulmonary function test
Description: Pulmonary function testing performed

Intervention type: OTHER
Intervention: Chest CT
Description: Chest CT scan to evaluate for pulmonary fibrosis

Intervention type: OTHER
Intervention: Sample collection
Description: Blood and urine sample collections

Intervention type: OTHER
Intervention: Sample collection
Description: Blood and urine sample collections

Intervention type: OTHER
Intervention: Sample collection
Description: Blood and urine sample collections

Intervention type: OTHER
Intervention: Sample collection
Description: Blood and urine sample collections
Study: NCT03791437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital chest drainage system
Description: patients who received Digital chest drainage system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Not use Digital chest drainage system
Description: patients who not received Digital chest drainage system( traditional drainage system)
Study: NCT02801162

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional ABG analyser
Description: pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional ABG analyser
Description: pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proxima 3®
Description: pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proxima 3®
Description: pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %